Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Stock Psychology

<< Previous

Bullboard Posts

Next >>

Comment by Journeytcon Aug 22, 2023 7:10pm

206 Views

Post# 35600858

RE:RE:RE:Stock Psychology

Half million for breast cancer! All those years holding off for AWARE one results, the breast cancer ICI combo distraction, and all that extra cost and share dilution. All since Matt put in charge. Directors should punt him and put an outside financial guy, an expert in divestiture in charge.

<< Previous

Bullboard Posts

Next >>

Canadian government approves Glencore’s takeover of Teck’s coal business